MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
- None.
- None.
Insights
The acceptance of the supplemental Biologics License Application (sBLA) by the FDA for MediWound's NexoBrid represents a significant step in the treatment of burn victims, potentially altering the standard of care. The global Phase 3 clinical trial, CIDS, which supports this sBLA, has demonstrated the safety and efficacy of NexoBrid in pediatric patients. This is crucial because the pediatric population has distinct physiological responses and recovery patterns compared to adults, making tailored treatments necessary.
From a medical research perspective, the enzymatic debridement offered by NexoBrid could reduce the need for surgical intervention, which is particularly beneficial in pediatric patients due to the risks associated with anesthesia and surgery in this demographic. Moreover, enzymatic debridement can be less painful and may preserve more of the viable tissue, which is essential for better functional and cosmetic outcomes, especially in a growing child.
However, it is important to monitor the long-term effects of such treatments, as the scar tissue's quality and the potential for growth-related complications can significantly impact the patient's quality of life. The backing by BARDA underscores the potential public health benefit and the government's interest in innovative treatments for mass casualty events.
The expansion of NexoBrid's indication to pediatric patients in the U.S. market could potentially increase MediWound's target demographic and market share. The prior approval in Europe and Japan suggests a favorable reception to the drug's efficacy and safety profile, which could bode well for its uptake in the U.S. upon approval for the pediatric indication.
Investors and stakeholders should note that the burn care market is highly specialized, with few effective non-surgical options available. Thus, the introduction of NexoBrid for pediatric use could disrupt the market dynamics and establish MediWound as a leader in enzymatic burn care therapies. Furthermore, the partnership with Vericel could provide additional commercialization expertise and resources, potentially accelerating market penetration and adoption post-approval.
However, the actual impact on MediWound's financials will depend on the pricing strategy, reimbursement policies and the ability to effectively communicate the benefits of NexoBrid to healthcare providers and patients. Market adoption rates are also influenced by existing treatment protocols and the conservatism often seen in pediatric care adoption of new treatments.
The FDA's acceptance of MediWound's sBLA filing for NexoBrid in pediatric patients is a pivotal event that could have a notable impact on the company's financial trajectory. Given the historical context where new treatments in the biopharmaceutical sector can lead to significant revenue streams, the expansion into the pediatric segment opens up a new, previously untapped market for MediWound.
Investors should consider the potential for increased revenue against the substantial costs associated with the development, clinical trials and marketing of NexoBrid. The investment by BARDA in the CIDS trial indicates government support, which may ease some of the financial burden and enhance investor confidence. Additionally, the partnership with Vericel could lead to shared costs and increased efficiency in commercialization efforts.
On the flip side, it is essential to remain aware of the regulatory risks and the possibility of delays or additional requirements from the FDA review process. Any such developments could affect the stock's performance and the company's financial outlook. Moreover, the competitive landscape, including any existing or emerging treatments, will also play a critical role in determining NexoBrid's financial success.
If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S.
NexoBrid is already approved for use for burn patients across all age groups in Europe and Japan
YAVNE, Israel, Jan. 09, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Food and Drug Administration (FDA) has completed their filing review and accepted a supplement to the NexoBrid® biologics license application (sBLA) for the removal of eschar in pediatric patients with deep partial- and/or full-thickness thermal burns.
NexoBrid, a topically administered biological drug that enzymatically removes nonviable burn tissue, received FDA approval in the U.S. in December 2022 for eschar removal in adult patients with deep partial-thickness and/or full-thickness thermal burns.
The sBLA seeks to expand the label for NexoBrid to include both adult and pediatric burn patients of all ages. It is based on the results of a global Phase 3 clinical trial, Children Innovation Debridement Study (CIDS), which evaluated the safety and efficacy of NexoBrid in hospitalized pediatric patients, as well as additional pediatric data available from Phase 3 and Phase 2 studies conducted during the clinical development of NexoBrid. Of note, the CIDS trial was funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services.
“The acceptance of the NexoBrid sBLA filing by the FDA marks an important milestone for MediWound and reinforces our commitment to redefine the standard of care for the treatment of severe burns across all age groups,” said Ofer Gonen, CEO of MediWound. “NexoBrid is already approved for the adult and pediatric populations in Europe and Japan, and we look forward to working with the FDA, alongside our partner Vericel, throughout the sBLA review process.”
About NexoBrid
NexoBrid® is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial- and/or full-thickness thermal burns without harming viable tissue. NexoBrid is approved in over 40 countries, including in United States, European Union and Japan, where it has been designated as an orphan biologic drug.
NexoBrid development has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under contract HHSO100201500035C. This contract provided funding and technical support for the pivotal U.S. Phase 3 clinical study (DETECT), the randomized, controlled pivotal clinical trial for use in the pediatric population (CIDS), the marketing approval registration process for NexoBrid as well as its procurement and availability under the expanded access treatment protocol (NEXT) in the U.S. Additional projects for evaluation of NexoBrid funded under the BARDA contract include establishment of a pre-emergency use data package and development of the health economic model to evaluate the cost savings impact to enable market adoption in the United States.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries.
MediWound’s first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Company’s lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant potential advantages over the
For more information visit www.mediwound.com and follow the Company on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
MediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.
Specifically, this press release contains forward-looking statements concerning the anticipated progress, development, expectations and commercial potential of our products and product candidates, including NexoBrid®. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated our expectations regarding future growth, market acceptance of our products and product candidates; our ability to maintain adequate protection of our intellectual property; competition risks; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future.
These and other significant factors are discussed in greater detail in MediWound’s annual report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 16, 2023 and Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound’s current views as of the date hereof and MediWound undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law.
| MediWound Contacts: | |
| Hani Luxenburg | Daniel Ferry |
| Chief Financial Officer | Managing Director |
| MediWound Ltd. | LifeSci Advisors, LLC |
| ir@mediwound.com | daniel@lifesciadvisors.com |
FAQ
What did MediWound announce regarding NexoBrid?
Where is NexoBrid already approved for use for burn patients?
What is the purpose of the sBLA for NexoBrid?
What is the phase of the clinical trial that provided the basis for the sBLA filing?
Who funded the CIDS trial?
